

1 Letter to the Editor

2 **Expansion of activated Treg cells inversely correlates with clinical severity in septic neonates.**

3

4 **Corresponding authors:**

5 Vincenzo Barnaba, MD

6 Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma

7 Viale del Policlinico 155, I-00161 Rome, Italy

8 phone: +39 6 491268; fax: +39 6 4938 3333;

9 email: vincenzo.barnaba@uniroma1.it

10 and

11 Paolo Rossi, MD, PhD

12 Dipartimento Pediatrico Universitario Ospedaliero (DPUO), Ospedale Pediatrico Bambin Gesù

13 Piazza Sant'Onofrio 4, 00165 Roma, Italy

14 Phone: +39 06 6859 2508

15 email: paolo.rossi@opbg.net

16

17 **Sources of funding:**

18 This work was supported by the following grants obtained by P.R.: Italian Ministry of Health;

19 "IRCCS Ospedale Pediatrico Bambino Gesù"; the following grants obtained by V.B.: Associazione

20 Italiana per la Ricerca sul Cancro (AIRC) (projects AIRC IG-2010/13 no. 10756 and IG-2015/17

21 no. 15199).

22 It was also supported by a grant obtained by S.P. from Italian Ministry of Education, University and

23 Research (FIRB-Futuro in ricerca RBFR12I3UB_002).

24 **Capsule summary**

25 Our work contributes to the definition of a possibly protective role of Tregs in neonatal severe
26 infections with particular attention to different molecules that may better define the phenotype and
27 role of the Treg subset.

28

29 **Key words**

30 Regulatory T cells; Infants; Neonates; Sepsis; Systemic Inflammatory Response Syndrome.

31

32 **Abbreviations**

33 act, activated; HD, healthy donor; MFI, mean fluorescence intensity; pts, patients; SIRS,
34 systemic inflammatory response syndrome; Tconvs, conventional T cells; Tregs, regulatory T
35 cells.

36 Word Count: 1080

37 To the Editor:

38 Current knowledge about regulatory T cells' (Tregs) function in early life is very limited. Tregs
39 represent a heterogeneous CD4⁺ T cell population addressed to maintain immunological self-
40 tolerance and immune homeostasis in various immune-mediated diseases including infectious
41 processes. It is known that circulating CD4⁺CD25⁺ Tregs increase during septic shock in adult,¹
42 while very few data exist about Tregs in neonatal infections. The aim of our study was to analyse
43 frequency/heterogeneity of Tregs in neonates with infectious and non-infectious systemic
44 inflammatory response syndrome (SIRS) (see Table E1 in Online Repository).

45 Firstly, we found that the percentage of FOXP3⁺CD127^{low} Tregs within the gate of CD4⁺ T cells in
46 mononuclear cells enriched from peripheral blood of neonates with sepsis or SIRS, as well as in
47 neonatal (CTRLs) and paediatric (PED) controls, resulted similar in all cohorts (Fig.E1A-B) (see
48 Figure E in Online Repository). However, when different subsets of Tregs were analysed
49 (CD45RA^{high}FOXP3^{low} resting [rest], CD45RA^{low}FOXP3^{high} activated [act], and
50 CD45RA^{low}FOXP3^{low} non-suppressive [non] Tregs),² (complete methodology available as Online
51 Repository Methods) a marked increase of circulating actTregs was observed in both septic and
52 SIRS neonates compared to CTRLs (Fig.E1A-C; Fig.1A). Using the EMA clinical and laboratory
53 criteria to diagnose neonatal sepsis,^{3, 4} we developed a composite score in order to evaluate the
54 clinical severity of enrolled patients. Importantly, an inverse correlation between actTreg frequency
55 and clinical score was detected in septic neonates (Fig.1B), suggesting that actTregs may limit
56 excessive sepsis-specific immunopathology. This hypothesis was supported by the evidence that
57 CD39, a membrane ectonucleotidase hydrolysing ATP and ADP to AMP and ultimately
58 contributing to the peculiar suppressive functions of Tregs,⁵ was expressed on Tregs more than
59 Tconvs (Fig.E2A), and on actTregs more than restTregs or nonTregs (Fig.1C). To explore the
60 mechanism of the high inter-individual variability in the CD39 expression on Tregs (Fig. 1D-E), we
61 analysed the single-nucleotide polymorphism (SNP) rs10748643 (A vs G) within the *ENTPDI*
62 gene.⁶ The allelic variation was closely related to CD39 levels in Tregs, but not in Tconvs; indeed,
63 GG homozygous and/or AG heterozygous individuals showed a higher frequency of CD39⁺ Tregs
64 compared to AA homozygous within each group (Fig.1D-E). In addition, a further increase of
65 CD39⁺ Tregs, but not Tconvs (Fig.1E-F), was shown in both sepsis and SIRS neonates as compared
66 with CTRLs, upon stratification by genotype, suggesting that both genetic signature and
67 inflammatory milieu contribute to the CD39 overexpression. As control, we analysed the genetic
68 contribution of the *ENTPDI* SNP in determining CD39 levels in cord blood, a context mostly
69 spared from T cell activation events (Fig.E2B-F).

70 To evaluate whether Tregs may modulate their phenotype during sepsis or SIRS, we quantified the
71 expression of OX40, a receptor belonging to the tumour necrosis factor receptor family specifically
72 up-regulated in highly suppressive tumour-infiltrating Tregs.⁷ OX40 was significantly more
73 expressed in CD39⁺ compared to CD39⁻, principally within the gate of Tregs rather than Tconvs
74 (Fig.E2G). Furthermore, a significant increment of OX40⁺ cells among CD39⁺ Tregs was detected
75 in sepsis and even more in SIRS neonates as compared with CTRLs (Fig.2A). Notably, CTRLs,
76 sepsis and SIRS neonates showed significantly higher OX40 expression in CD39⁺ than PED. Also
77 in Tconvs, OX40 was markedly higher in CD39⁺ respect to CD39⁻ cells (Fig.E2H), but at lower
78 levels than Tregs (Fig.2A). These data suggest that Tregs, but not Tconvs, up-regulated OX40
79 during both sepsis and non-infectious SIRS, especially in suppressive CD39⁺ cells accounting for
80 the possible homeostatic role of Tregs in these pathologic conditions. Consistent with this
81 hypothesis, the percentage of OX40⁺ Tregs was inversely correlated with the clinical score in septic
82 neonates (Fig.2B), suggesting OX40 induction on Tregs as a protective mechanism in neonatal
83 sepsis. Interestingly, OX40⁺ and CD39⁺ Tregs were more represented within Helios^{high} than
84 Helios^{low} cells irrespective of cohorts (Fig.E3A), strongly suggesting their belonging to a stable
85 Treg population. Indeed, the transcription factor Helios has been described to distinguish thymic-
86 derived (committed/stable) FOXP3⁺ Treg from peripherally induced FOXP3⁺ Tregs.⁸

87 To investigate whether particular cytokines may provide selective signals inducing OX40 up-
88 regulation during neonatal sepsis or SIRS, first we analysed the percentage of circulating T cells
89 producing IFN- γ and/or TNF- α by flow cytometry. Notably, IFN- γ -single or IFN- γ /TNF- α -double
90 producing T cells were poorly detectable in both CD4⁺ and CD8⁺ of neonates compared to PED and
91 adult healthy donors (AD) (Fig.E3B-C), suggesting a neonatal incompetence to generate IFN- γ -
92 mediated adaptive responses. Consistently with this hypothesis, T cells from all neonatal groups
93 prevalently expressed a naïve phenotype (data not shown). By contrast, TNF- α - producing T cells
94 (CD4⁺ and CD8⁺) were similarly represented in all neonatal cohorts (Fig.E3B-C), as well as in PED
95 and AD (Fig.E3B-C), despite an increased plasma TNF- α level was detected in septic neonates
96 (data not shown). Further studies are needed to investigate whether additional sources (monocytes,
97 dendritic cells) may contribute to increase TNF- α levels in septic neonates. Notably, we found that
98 CD120b (TNFR2) was expressed at higher levels in Tregs than in Tconvs (Fig.E4A), as well as in
99 CD39⁺ respect to CD39⁻ Tregs (Fig.E4A), and even in septic or SIRS neonates significantly more
100 than in CTRLs (Fig.2C). Interestingly, the percentage of OX40⁺ cells within CD39⁺ Tregs directly
101 correlated with the percentage of CD120b⁺ cells (Fig.2D), as to support that the preferential OX40
102 expression on CD39⁺ Tregs *in vivo* might be particularly due to the higher susceptibility to TNF- α
103 by CD39⁺CD120b⁺ Tregs, principally during neonatal sepsis and SIRS. In line with this finding, *in*

104 *in vitro* experiments revealed that the overnight TNF- α treatment of fresh PBMCs obtained from
105 healthy CTRLs enhanced the level of OX40 expression at a greater degree in Tregs than in Tconvs
106 (Fig.E4B). TNF- α induced a significant OX40 up-regulation principally on CD39⁺ Tregs (Fig.2E),
107 suggesting that CD39⁺ Tregs are particularly prone to up-regulate OX40.

108 Then, based on the evidence of increased plasma levels of IL-33 (cytokine belonging to the IL-1
109 superfamily) in SIRS neonates (data not shown), and of a previous report demonstrating an IL-33-
110 dependent up-regulation of OX40 on mouse Tregs *in vitro*,⁹ we investigated the role of this
111 cytokine in activating Tregs in terms of OX40 up-regulation *in vitro* by using PBMCs from adult
112 HDs. Interestingly, PBMCs treated with IL-33 were able to up-regulate OX40 expression at a
113 significant higher level in total Tregs or CD39⁺ Tregs than in Tconv counterpart (Fig.E4C).
114 Notably, a positive correlation between IL-33 plasma concentration and the percentage of OX40⁺ in
115 total Tregs was observed in all neonatal cohorts (Fig.2F).

116 Taken together, our data support the hypothesis that actTregs, especially OX40⁺ Tregs showing
117 CD39⁺, Helios⁺, and CD120b⁺ phenotype, counteract excessive immunopathology in neonatal
118 sepsis, and that their functions are modulated via prominent inflammatory cytokines, such as TNF-
119 α and IL-33, during infective and non-infective SIRS.

120

121 Eleonora Timperi^{1*}, PhD;

122 Laura Folgori^{2*}, MD;

123 Donato Amodio², MD;

124 Maia De Luca², MD;

125 Sara Chiurchiù², MD;

126 Silvia Piconese^{1,3}, PhD;

127 Silvia Di Cesare², MS;

128 Ilenia Pacella¹, MS;

129 Carmela Martire¹, MS;

130 Giulia Bonatti², MD;

131 Seila Perrone⁴, MD;

132 Terenzio Boni⁴, MD;

133 Genni Enza Marcovecchio², MS;

134 Antonino Reale⁵, MD;

135 Francesco Parisi⁶, MD;

136 Andrea Dotta⁷, MD;

137 Vincenzo Barnaba^{1,3}, MD

138 Paolo Rossi², MD, PhD.

139

140 *Equally contributing authors

141

142 *¹Department of Internal Medicine and Medical Specialities, “Sapienza” Università di Roma,*
143 *Policlinico Umberto I, Rome, Italy*

144 *²University Department of Pediatrics, Bambino Gesù Children’s Hospital, University of Rome “Tor*
145 *Vergata”, Rome, Italy*

146 *³Pasteur Institute – Cenci Bolognetti Foundation, Rome, Italy*

147 *⁴Department of Gynecological Obstetrics Sciences and Urological Sciences, “Sapienza” Università*
148 *di Roma, Policlinico Umberto I, Rome, Italy*

149 *⁵Emergency Department, Bambino Gesù Children’s Hospital, Rome, Italy*

150 *⁶Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children’s Hospital,*
151 *Rome, Italy*

152 *⁷Neonatal Intensive Care Unit, Department of Medical and Surgical Neonatology, Bambino Gesù*
153 *Children’s Hospital, Rome, Italy*

154 **References**

- 155 1. Monneret G, Debard AL, Venet F, Bohe J, Hequet O, Bienvenu J, et al. Marked elevation of
156 human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit
157 Care Med 2003; 31:2068-71.
- 158 2. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation
159 and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription
160 factor. Immunity 2009; 30:899-911.
- 161 3. Report on the Expert Meeting on Neonatal and Paediatric Sepsis. Available from:
162 http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/12/WC500100199.pdf. . Last access
163 10 February 2015
- 164 4. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric S.
165 International pediatric sepsis consensus conference: definitions for sepsis and organ
166 dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8.
- 167 5. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al.
168 Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP
169 and immune suppression. Blood 2007; 110:1225-32.
- 170 6. Friedman DJ, Kunzli BM, YI AR, Sevigny J, Berberat PO, Enyoji K, et al. From the Cover:
171 CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase
172 susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A 2009; 106:16788-
173 93.
- 174 7. Piconese S, Timperi E, Pacella I, Schinzari V, Tripodo C, Rossi M, et al. Human OX40
175 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-
176 infected liver tissue. Hepatology 2014; 60:1494-507.
- 177 8. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression
178 of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from
179 peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184:3433-41.
- 180 9. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelman K, Wohlfert EA, et al. The
181 alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014; 513:564-8.

182

183

184 **Figure legends**

185 *Figure 1. Frequency of actTregs inversely correlates with septic score.*

186 (A) actTreg frequency estimated by FCM as the percentage of CD45RA^{low}FOXP3^{high} Tregs among
187 CD4⁺ T cells (CTRL=28; sepsis=10; SIRS=19; PED=21). **P*<0.05, ***P*<0.01, by Mann-Whitney's
188 test, two-tailed.

189 (B) Spearman's correlation (*r*) between actTregs/CD4⁺ T cell percentage and clinical severity score
190 in septic neonates. **P*<0.05.

191 (C) Representative FCM data (CTRL sample) showing CD45RA *versus* FOXP3 profile (left);
192 overlay of CD39 MFI (right) of CD45RA^{low}FOXP3⁺ (actTreg), CD45RA^{high}FOXP3^{low} (restTreg),
193 CD45RA^{low}FOXP3⁻ (nonTreg) subsets.

194 (D) Representative FCM plots of CD39 *vs* FOXP3 expression in gated Tregs, showing the
195 frequency of CD39⁺, according to AA or AG+GG genotypes in the *ENTPDI* gene.

196 (E) Frequency of CD39⁺ cells in gated Tregs in all cohorts according to AA or AG+GG genotypes
197 in the *ENTPDI* gene (CTRL=23; sepsis=10; SIRS=15; PED=21). **P*<0.05, ***P*<0.01, ****P*<0.005
198 by Mann-Whitney's test, two-tailed.

199 (F) Frequency of CD39⁺ cells in gated Tconvs in all cohorts according to AA or AG+GG genotypes
200 in the *ENTPDI* gene (CTRL=23; sepsis=10; SIRS=15; PED=21). **P*<0.05, ***P*<0.01, ****P*<0.005
201 by Mann-Whitney's test, two-tailed.

202

203 *Figure 2. Frequency of OX40⁺ Tregs is up-regulated in sepsis and SIRS neonates and inversely*
204 *correlates with septic score.*

205 (A) Frequency of OX40⁺ in subdivided CD39⁺ and CD39⁻ Treg subsets in all groups (CTRL=32;
206 sepsis=11; SIRS=20; PED=21). **P*<0.05, ***P*<0.01, ****P*<0.005, *****P*<0.0001 by Mann-
207 Whitney's test two-tailed and Wilcoxon's matched-pairs test, two-tailed.

208 (B) Spearman's correlation (*r*) between frequency of OX40⁺ Tregs and clinical severity score in
209 septic neonates (Table I). **P*<0.05.

210 (C) PBMCs from healthy neonatal controls were cultured ON with or without TNF- α . OX40 MFI
211 was evaluated in Tregs and Tconvs. **P*<0.05 by Paired T-test, two-tailed.

212 (D) Frequency of CD120b⁺ cells in CD39⁺ and CD39⁻ Tregs (CTRL=5; sepsis=6; SIRS=4).

213 (E) Pearson's correlation (*r*) between frequency of CD120b⁺ cells and OX40⁺ cells within CD39⁺
214 Tregs in all cohorts. ***P*<0.01.

215 (F) Spearman's correlation (*r*) between frequency of OX40⁺ Tregs and IL-33 plasma concentration
216 in all cohorts. ****P*<0.005.